.jpeg)
What is the brand name of Avelumab?
In several multicenter studies, avelumab therapy produced objective responses in patients with advanced, metastatic or unresectable malignancies, and some patients achieved long-term remissions. Avelumab was approved in the United States in 2017 for metastatic Merkel cell carcinoma and advanced refractory urothelial bladder cancer, and was subsequently approved in combination with axitinib for advanced renal cell carcinoma. Avelumab is available in 200 mg (20 mg/ml) single-use 10 ml vials under the brand name Bavencio.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
